Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study

Background/Aims: Infliximab treatment failure in patients with inflammatory bowel disease may result from sub-optimal infliximab trough level. An understanding of pharmacokinetics (PKs) is important to maintain an optimal trough level. PK studies of the switch to subcutaneous (SC) infliximab from in...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Joo Hye Song, Sung Noh Hong, Myeong Gyu Kim, Minjung Kim, Seong Kyung Kim, Eun Ran Kim, Dong Kyung Chang, Young-Ho Kim
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Gastroenterology Council for Gut and Liver 2025-05-01
Edice:	Gut and Liver
Témata:	infliximab; pharmacokinetic model; intravenous; subcutaneous; inflammatory bowel diseases
On-line přístup:	http://gutnliver.org/journal/view.html?doi=10.5009/gnl240503
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!